Inactive Instrument

EnzymeBioSystems

Equities

Biotechnology & Medical Research

EnzymeBioSystems Appoints Gary Rojewski as CEO, Effective June 2, 2014

May 23, 2014 at 11:30 am

EnzymeBioSystems announced the appointment of Gary Rojewski as its new CEO, effective June 2, 2014. Mr. Rojewski will be responsible for leading and managing EnzymeBioSystems' business operations, including regulatory affairs with government agencies. Mr. Rojewski has 29-years experience in the pharmaceutical industry.

Latest news about EnzymeBioSystems

EnzymeBioSystems Announces Management Changes	04/01/18	CI
EnzymeBioSystems Announces Change of its Corporate Headquarters	14/12/17	CI
EnzymeBioSystems announced that it has received $0.779526 million in funding	23/10/17	CI
EnzymeBioSystems announced a financing transaction	05/09/17	CI
The Board of EnzymeBioSystems announced the spin-off of Shareholder Acquisition Corp.	11/01/17	CI
EnzymeBioSystems Auditor Raises 'Going Concern' Doubt	11/11/15	CI
Enzymebiosystems Announces Change of its Principal Executive Offices	14/10/15	CI
EnzymeBioSystems will Change its Ticker to ENZBE from ENZB	02/10/15	CI
EnzymeBioSystems Announces Executive Changes	25/09/15	CI
EnzymeBioSystems Provides Product Development Update	20/08/15	CI
EnzymeBioSystems will Change its Ticker to ENZB from ENZB.D	16/07/15	CI
EnzymeBioSystems will Change its Ticker to ENZBD from ENZB	18/06/15	CI
EnzymeBioSystems Announces Preclinical Xenograft Studies Show Positive Results for Amooranin	10/12/14	CI
EnzymeBioSystems Announces Management Changes	23/10/14	CI
EnzymeBioSystems Changes its Principal Executive Office	23/10/14	CI
EnzymeBioSystems Appoints Gary Rojewski as CEO, Effective June 2, 2014	23/05/14	CI

Chart EnzymeBioSystems

Duration

Period

More charts

Company Profile

EnzymeBioSystems is a development-stage company. The Company researches specialty enzymes and enzyme related products. The Company utilizes enzyme technologies to develop commercial solutions for a range of applications within the specialty chemical industry. It seeks to develop specialty enzymes to eliminate the side effects and toxicity of the new commercially developed products. The Company's product candidate, Amooranin, is indicated for the treatment of multiple breast cancer. Amooranin is a triterpene acid with a structure isolated from the stem bark of Amoora rohituka, a tropical tree in India. The Company intends to research the study of the use of Amooranin. Specifically, the two areas of this study includes an exam of the in vitro cytotoxicity of Amooranin against hepatocellular carcinoma cells, and investigate the dose responsive antitumor actions of Amooranin against chemically induced hepatic tumorgenesis in rats and dogs.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research